Survey Study About Endoscopy During COVID-19 Pandemic for IBD Doctors

NCT04970849 | Completed DMC FDA Drug

• 1 other identifier: I2020001357
• Study Type: observational
• Target: 200
• Locations: 1 country
• Sites: 1

Brief Summary

Performance of diagnostic or therapeutic endoscopic procedures in inflammatory bowel disease (IBD) patients can be challenging during a viral pandemic; the main concerns being the safety and protection of patients and health care providers (HCP). The aim of this study is to identify endoscopic practice patterns and outcomes of IBD and coronavirus disease 19 (COVID-19) with a worldwide survey of HCP.

Conditions

Inflammatory Bowel Diseases

Outcome Measures

Primary Outcomes (1)

• The influence of covid-19 pandemic on endoscopic practice by IBD endoscopist

  The incidence of scheduled IBD endoscopies were postponed or cancelled due to the pandemic.

  1 week

Secondary Outcomes (1)

• The incidence of COVID19 in IBD patients who underwent endoscopy

  1 week

Study Arms (1)

one group that is IBD endoscopist who perform the endoscopy for IBD patients

Complete the questionnaire online

Other: observation

Interventions

observation OTHER

IBD doctors who perform the endoscopy perform the questionnaire

Also known as: endoscopy with no drug

one group that is IBD endoscopist who perform the endoscopy for IBD patients

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

The content of survey included: The number of procedures, the indication of endoscopy, the number of patients with IBD diagnosed Covid-19, and the influence of the epidemic situation on the diagnosis and treatment of IBD.

You may qualify if:

• Doctors who are involved in the endoscopic treatment of IBD patients;
• The endoscopist reads and signs an informed consent online. -

You may not qualify if:

• Doctors who are not involved in the endoscopic treatment of IBD patients
• Doctors who need the help of an agent, a witness, or someone else who can not complete the questionnaire independently.

Sponsors & Collaborators

• Second Affiliated Hospital, School of Medicine, Zhejiang University: lead

Study Sites (1)

Second Affiliated Hospital Zhejiang University School of Medicine

Zhengzhou, Hangzhou, 310000, China

Location

Related Publications (1)

• Mao R, Liang J, Shen J, Ghosh S, Zhu LR, Yang H, Wu KC, Chen MH; Chinese Society of IBD, Chinese Elite IBD Union; Chinese IBD Quality Care Evaluation Center Committee. Implications of COVID-19 for patients with pre-existing digestive diseases. Lancet Gastroenterol Hepatol. 2020 May;5(5):425-427. doi: 10.1016/S2468-1253(20)30076-5. Epub 2020 Mar 11. No abstract available.

  PMID: 32171057 RESULT

MeSH Terms

Conditions

Inflammatory Bowel Diseases

Interventions

Observation; Endoscopy

Condition Hierarchy (Ancestors)

Gastroenteritis; Gastrointestinal Diseases; Digestive System Diseases; Intestinal Diseases

Intervention Hierarchy (Ancestors)

Methods; Investigative Techniques; Diagnostic Techniques, Surgical; Diagnostic Techniques and Procedures; Diagnosis; Minimally Invasive Surgical Procedures; Surgical Procedures, Operative

Study Officials

• Yan Chen

  浙江大学医学院附属第二医院

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 15, 2021
• First Posted: July 21, 2021
• Study Start: July 15, 2021
• Primary Completion: July 15, 2021
• Study Completion: July 15, 2021
• Last Updated: July 21, 2021

Record last verified: 2020-04

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL
• Time Frame: now is available
• Access Criteria: All the doctors

Locations

CN (1)